A PYMNTS Company

US: Pfizer, Ranbaxy overcome pay-for-delay claims

By  |  September 14, 2014

Two pharmaceutical conglomerates emerged victorious Friday in a lawsuit accusing the companies of colluding to delay the release of generic medication for sale in a pay-for-delay scheme, say reports.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Pfizer Inc and India-based Ranbaxy Laboratories won a dismissal of the lawsuit filed by retailers and distribution companies. The plaintiffs argued that the two had conspired to delay the release of the generic, cheaper form of Lipitor.

    According to reports, the suit alleged that the companies settled a patent dispute in 2008 that saw Pfizer drop patent infringement claims against Ranbaxy and, in exchange, Ranbaxy would not enter the Lipitor market until November 2011.

    But a federal judge ruled Friday that the plaintiffs failed to argue the case with sufficient detail, according to reports.

    Specifically, the judge ruled that the plaintiffs did not argue a monetary value of the 2008 argument.

    Full content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.